Impact of genetic diagnostics on drug development strategy. (Q53597217)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	Impact of genetic diagnostics on drug development strategy.	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16699494

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16699494

review article

1 reference

stated in

Europe PubMed Central

title

Impact of genetic diagnostics on drug development strategy. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16699494

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16699494

author name string

Ryan P Million

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16699494

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16699494

publication date

12 May 2006

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16699494

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16699494

published in

Nature Reviews Drug Discovery

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16699494

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16699494

volume

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16699494

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16699494

issue

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16699494

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16699494

page(s)

459-462

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16699494

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16699494

cites work

Finishing the euchromatic sequence of the human genome

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRD2034

retrieved

21 January 2018

A genetic model for colorectal tumorigenesis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRD2034

retrieved

21 January 2018

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRD2034

retrieved

21 January 2018

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRD2034

retrieved

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRD2034

retrieved

21 January 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRD2034

retrieved

21 January 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRD2034

retrieved

21 January 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRD2034

retrieved

21 January 2018

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRD2034

retrieved

21 January 2018

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRD2034

retrieved

21 January 2018

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRD2034

retrieved

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRD2034

retrieved

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRD2034

retrieved

21 January 2018

Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRD2034

retrieved

21 January 2018

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRD2034

retrieved

21 January 2018

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRD2034

retrieved

21 January 2018

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRD2034

retrieved

21 January 2018

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRD2034

retrieved

21 January 2018

The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRD2034

retrieved

31 March 2020

Identifiers

DOI

10.1038/NRD2034

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16699494

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16699494

PubMed publication ID

16699494

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16699494

retrieved

16 May 2018

reference URL

http://europepmc.org/abstract/MED/16699494

ResearchGate publication ID

7082913

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53597217&oldid=2212221906"